At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 256 target
Drug / intervention
IBI319drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors
In Brief
A Phase 1 clinical trial evaluating IBI319 for Advanced Malignant Tumors. Targeting 256 participants across 1 site.
Detailed Summary
An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and preliminary efficacy of IBI319 in patients with advanced malignant tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Tumors
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202120222023202420252026
First PostedJan 2021
Enrollment StartApr 2021
Primary CompletionDec 2022
Study CompletionJun 2023
TodayJul 2026
First PostedJan 13, 2021
Enrollment StartApr 28, 2021
Primary CompletionDec 21, 2022
Study CompletionJun 21, 2023
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 5.5 years ago
Interventions
IBI319drug
Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.